Drug cargo, 169
Drug-loaded EVs, 159
Dynamic PET, 293
E
Ectosomes, 130
Electrostatic interaction, 191
Encapsulation, 191
Enhanced permeability and retention effect. See
(EPR)
Enzymatic oxidation, 89
Enzyme-mediated reaction, 189
Epigenetic modification, 392
Evans blue, 111
EV-based therapeutics, 173
EV-mediated intercellular communication, 129
Excretion, 347
Exosome-mimetic nanovesicles, 175
Exosomes, 6, 130, 160, 168
DC-derived exosomes, 172
Erythrocyte-derived exosomes, 177
MSC-derived exosomes, 171
Self-derived exosomes, 178
Exosomes in regenerative medicine, 170
Extracellular vesicles. See (EVs)
Cancer cell-derived EVs, 132
mesenchymal stem cell-derived EVs, 135
Extrinsic radiolabeling, 220
F
FccR, 400
FcRn, 400
Film hydration method, 191
Filtration barriers in the glomerulus, 350
Fluorescence imaging, 412
Fluorescence labeling, 155
Fluorine-18, 242
Fluorine-18-labeled ADIBO-synthon, 271
Fluorine-18-labeled Azides Building Blocks,
271
Fluorine-18-labeled Tz secondary agent, 258
Folate hydrolase 1, 236
Folate receptors, 236
Functionalization of nanoparticles, 213
G
Gallium-67, 60
Gallium-68, 60
Gamma camera, 281
Geometry of targeting molecules, 240
Gjedde–Patlak plot, 300
Glomerular basement membrane. See (GBM)
Glutamate carboxypeptidase II, 236
Gold nanoparticles, 18, 321, 413, 437
Graphene, 5, 80
Graphene based MRI Imaging, 94
Graphene oxides. See (GOs)
Graphene quantum dots. See (GQDs)
Graphical analysis, 300
H
Hepatic lobule, 360
Hepatobiliary excretion, 359
High-density lipoprotein. See (HDL)
Hollow mesoporous silica nanoparticles. See
(HMSNs)
Hot-plus-cold precursors, 220
Huisgen 1,3-dipolar cycloaddition, 252
Human serum albumin. See (HSA)
Humoral mediators, 392
Hyaluronic acid. See (HA)
Hydrodynamic diameters, 349
Hydrodynamic size, 315
Hydrophilization, 233, 337
Hydrophobic interactions, 186
Hydrophobicity, 213, 233, 331
Hydroxyl group, 188
Hypersensitivity reactions, 379
I
Image-guided PDT, 52
Image guided therapy, 243
Immune response, 5, 339
Immunoglobulins, 392
In vitro companion diagnostics, 5
In vivo integrity of radiolabeled nanomaterials,
241
In vivo SERS Imaging, 418
Indium-111, 66
Individual radiation dosimetry, 4
Innate immunity, 390
Innate lymphoid cell, 390
Innate therapeutic ability, 169
Inorganic nanoparticles, 15, 192
p–p interaction, 191
Internal radiation therapy, 433
Internal radiotherapy, 244
Intrinsic radiolabeling, 220
Investigational new drug. See (IND)
Iron oxide nanoparticles. See (IONPs)
K
Kupffer cells, 395, 396, 398
L
Labeling only the intact exosomes, 177
444
Index
Drug-loaded EVs, 159
Dynamic PET, 293
E
Ectosomes, 130
Electrostatic interaction, 191
Encapsulation, 191
Enhanced permeability and retention effect. See
(EPR)
Enzymatic oxidation, 89
Enzyme-mediated reaction, 189
Epigenetic modification, 392
Evans blue, 111
EV-based therapeutics, 173
EV-mediated intercellular communication, 129
Excretion, 347
Exosome-mimetic nanovesicles, 175
Exosomes, 6, 130, 160, 168
DC-derived exosomes, 172
Erythrocyte-derived exosomes, 177
MSC-derived exosomes, 171
Self-derived exosomes, 178
Exosomes in regenerative medicine, 170
Extracellular vesicles. See (EVs)
Cancer cell-derived EVs, 132
mesenchymal stem cell-derived EVs, 135
Extrinsic radiolabeling, 220
F
FccR, 400
FcRn, 400
Film hydration method, 191
Filtration barriers in the glomerulus, 350
Fluorescence imaging, 412
Fluorescence labeling, 155
Fluorine-18, 242
Fluorine-18-labeled ADIBO-synthon, 271
Fluorine-18-labeled Azides Building Blocks,
271
Fluorine-18-labeled Tz secondary agent, 258
Folate hydrolase 1, 236
Folate receptors, 236
Functionalization of nanoparticles, 213
G
Gallium-67, 60
Gallium-68, 60
Gamma camera, 281
Geometry of targeting molecules, 240
Gjedde–Patlak plot, 300
Glomerular basement membrane. See (GBM)
Glutamate carboxypeptidase II, 236
Gold nanoparticles, 18, 321, 413, 437
Graphene, 5, 80
Graphene based MRI Imaging, 94
Graphene oxides. See (GOs)
Graphene quantum dots. See (GQDs)
Graphical analysis, 300
H
Hepatic lobule, 360
Hepatobiliary excretion, 359
High-density lipoprotein. See (HDL)
Hollow mesoporous silica nanoparticles. See
(HMSNs)
Hot-plus-cold precursors, 220
Huisgen 1,3-dipolar cycloaddition, 252
Human serum albumin. See (HSA)
Humoral mediators, 392
Hyaluronic acid. See (HA)
Hydrodynamic diameters, 349
Hydrodynamic size, 315
Hydrophilization, 233, 337
Hydrophobic interactions, 186
Hydrophobicity, 213, 233, 331
Hydroxyl group, 188
Hypersensitivity reactions, 379
I
Image-guided PDT, 52
Image guided therapy, 243
Immune response, 5, 339
Immunoglobulins, 392
In vitro companion diagnostics, 5
In vivo integrity of radiolabeled nanomaterials,
241
In vivo SERS Imaging, 418
Indium-111, 66
Individual radiation dosimetry, 4
Innate immunity, 390
Innate lymphoid cell, 390
Innate therapeutic ability, 169
Inorganic nanoparticles, 15, 192
p–p interaction, 191
Internal radiation therapy, 433
Internal radiotherapy, 244
Intrinsic radiolabeling, 220
Investigational new drug. See (IND)
Iron oxide nanoparticles. See (IONPs)
K
Kupffer cells, 395, 396, 398
L
Labeling only the intact exosomes, 177
444
Index